FDA Grants Accelerated Approval for First Treatment for Barth Syndrome, Forzinity
THURSDAY, Sept. 25, 2025 -- The U.S. Food and Drug Administration granted accelerated approval to Forzinity (elamipretide) injection as the first treatment for Barth syndrome.
Barth syndrome is a rare, serious, and life-threatening disease of the mitochondria and Forzinity works by binding to the inner part of the mitochondria, improving their structure and function. Forzinity is administered subcutaneously once daily.
The approval is based on improved strength of the muscle used to straighten the leg at the knee, which is reasonably likely to predict patient benefit such as an ability to stand more easily or walk farther. The FDA, as a condition of accelerated approval, is requiring a postapproval randomized, double-blind, placebo-controlled trial to confirm that the changes seen on knee muscle strength translate into patient benefit. The most common side effects reported in clinical trials were mild-to-moderate injection site reactions, although serious reactions were also reported.
"The FDA remains committed to facilitating the development of effective and safe therapies for rare diseases and will continue to work diligently to help ensure patients with rare diseases have access to innovative treatments," George Tidmarsh, M.D., Ph.D., director of the FDA Center for Drug Evaluation and Research, said in a statement.
Accelerated approval of Forzinity was granted to Stealth Biotherapeutics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Personal Storytelling During Medical Training Aids Learning
THURSDAY, Sept. 25, 2025 -- A student-led program in which medical students share their own personal stories with illness during a preclinical curriculum enhances learning...
Clinical Practice Guidelines Issued for Diabetes Distress
THURSDAY, Sept. 25, 2025 -- The first clinical practice guidelines on assessment and management of diabetes distress among adults were presented at the annual meeting of the...
Older Adults Can Regain Well-Being
THURSDAY, Sept. 25, 2025 -- Older adults can regain well-being, according to a study published online Sept. 24 in PLOS ONE. Mabel Ho, Ph.D., and Esme Fuller-Thomson, Ph.D...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.